Centenarians help open new longevity drug pathways

With the number of centenarians growing steadily, researchers have been probing the genetic reasons that explain their longevity. And they believe that an increasingly sophisticated understanding of genetics will point the way to a new generation of drugs that can both extend life and dramatically improve the quality of the years that we have. Article

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.